A graphic that shows an overview of Mounjaro 15 mg or maximum tolerated dose plus metformin vs intensified conventional care plus metformin. SURPASS-EARLY is a 208-week study with primary endpoint at 104 weeks. At baseline, adult participants were recently diagnosed with type 2 diabetes within 0 to 4 years and on metformin alone. At week 0, participants were randomized (1:1) to receive either Mounjaro (15 mg or maximum tolerated dose) plus metformin or intensified conventional care plus metformin. Participants who were randomized to receive Mounjaro had a dose escalation period of 24 weeks. Participants who were randomized to the intensified conventional care arm received metformin plus any approved glucose-lowering medication (excluding tirzepatide) alone or in combination, including glucagon-like peptide-1 receptor agonist, sodium-glucose co-transporter 2 inhibitor, sulfonylurea, dipeptidyl peptidase-4 inhibitor, or insulin. ICC Arm: Patients were to be assessed at each of their study visits (monthly for the first 6 months and then 3-monthly starting at month 8) and treatment was to be intensified to reach glycemic control (within a non-diabetic range) safely according to local treatment guidelines.